We have studied the effect of intrathecal administration of N-methyl-D-aspartate (NMDA) receptor antagonists on the minimum alveolar anaesthetic concentration (MAC) of isoflurane in rats. In Wistar rats fitted with indwelling intrathecal catheters, we determined the MAC of isoflurane after administration of a competitive NMDA receptor antagonist APV (0.01, 0.1, 1.0, 10, 30 µg), a non-competitive NMDA receptor antagonist, MK801 (0.1, 1.0, 10, 30 µg), NMDA (0.01, 0.1, 1.0, 10, 30 µg) and saline. APV at all doses except 0.01 g decreased MAC by 17.1-32 % (P : 0.001 and P : 0.0001). Despite the widespread use of inhalation anaesthetics, the mechanisms and sites of action of most agents remain unknown. Many experiments have been directed towards the assessment of anaesthetic effects on the cerebral cortex. However, we know that inhalation anaesthetics exert significant effects elsewhere, such as on the spinal cord [1]. It is not known if the site of anaesthetic action is the cortex or spinal cord. In a recent study in the rat, cortical structures were removed without significantly altering the minimum alveolar anaesthetic concentration (MAC) of the inhalation anaesthetics [2] , suggesting that the relevant sites for MAC determination are the brain stem and the spinal cord. The potency of inhalation anaesthetics is defined as the MAC required to prevent movement in 50 % of test subjects. A state of anaesthesia is, therefore, defined in terms of the motor response to a noxious stimulus, usually a flexion withdrawal reflex, mediated at the spinal cord. A role for excitatory amino acids (EAA) in nociception is suggested by the fact that noxious stimulation causes release of glutamate and aspartate in the spinal cord dorsal horn. Intrathecal administration of N-methyl-D-aspartate (NMDA) produces a rapid, transient, dose-dependent hyperalgesia. This hyperalgesia is blocked reversibly by prior treatment with the selective NMDA receptor antagonist, APV (2-amino-5-phosphonopentanoic acid) [3] . It has also been shown that the release of peptide and of an amino acid neurotransmitter from primary afferents is not abolished by inhalation anaesthetics. A recent study has shown that the systemic administration of NMDA receptor antagonists reduces the MAC of isoflurane [4] .
Despite the widespread use of inhalation anaesthetics, the mechanisms and sites of action of most agents remain unknown. Many experiments have been directed towards the assessment of anaesthetic effects on the cerebral cortex. However, we know that inhalation anaesthetics exert significant effects elsewhere, such as on the spinal cord [1] . It is not known if the site of anaesthetic action is the cortex or spinal cord. In a recent study in the rat, cortical structures were removed without significantly altering the minimum alveolar anaesthetic concentration (MAC) of the inhalation anaesthetics [2] , suggesting that the relevant sites for MAC determination are the brain stem and the spinal cord. The potency of inhalation anaesthetics is defined as the MAC required to prevent movement in 50 % of test subjects. A state of anaesthesia is, therefore, defined in terms of the motor response to a noxious stimulus, usually a flexion withdrawal reflex, mediated at the spinal cord. A role for excitatory amino acids (EAA) in nociception is suggested by the fact that noxious stimulation causes release of glutamate and aspartate in the spinal cord dorsal horn. Intrathecal administration of N-methyl-D-aspartate (NMDA) produces a rapid, transient, dose-dependent hyperalgesia. This hyperalgesia is blocked reversibly by prior treatment with the selective NMDA receptor antagonist, APV (2-amino-5-phosphonopentanoic acid) [3] . It has also been shown that the release of peptide and of an amino acid neurotransmitter from primary afferents is not abolished by inhalation anaesthetics. A recent study has shown that the systemic administration of NMDA receptor antagonists reduces the MAC of isoflurane [4] .
The purpose of this study was to investigate in rats the effect of intrathecal administration of an NMDA receptor antagonist on the MAC of isoflurane.
Methods and results
This investigation was approved by the Animal Care Committee of Gunma University. Male Wistar rats (280-320 g) were fitted with indwelling intrathecal catheters by methods described previously [5] .In brief, the rat was mounted in a conventional stereotaxic instrument under halothane anaesthesia. Chronic intrathecal catheters were placed by passing a PE10 catheter through an incision in the atlantooccipital membrane to a position 8 cm caudal to the cisterna at the level of the lumbar enlargement. The catheter was externalized on the top of the skull and the wound was closed with 3-0 silk sutures. Preliminary trials with Evans Blue dye added to the injected solution had confirmed the lumbar enlargement. Rats with postoperative neurological deficits were killed promptly with an overdose of barbiturate. MAC was measured 4-9 days after intrathecal implantation of the catheter.
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10 µl. Animals were allocated randomly to 10 groups of six rats each, one control group and nine NMDA antagonist groups: APV 0.01-30 µg (five groups) and MK801 0.1-30 µg (four groups). If the MAC was reduced by the NMDA receptor antagonist, NMDA was administered intrathecally to reverse the effect. The dose of NMDA ranged from 0.01 to 30 µg. For all animals, anaesthesia was induced with 4 % halothane in oxygen by placing the rats in an induction chamber for 3-5 min. After tracheotomy, each animal was intubated with a 14-gauge polyethylene catheter. Rats breathed spontaneously through a non-rebreathing circuit. The oxygen supply to the isoflurane vaporizer was kept at 2 litre min Ϫ1 throughout the experiments. A polyethylene catheter (PE50) was inserted through the wall of the ventilatory tubing, and the tip of the sampling tube was positioned distal to the tracheostomy; this arrangement permitted sampling of endtidal gases. For arterial pressure monitoring and blood sampling, one femoral artery was catheterized with a polyethylene catheter (PE50). Rectal temperature was maintained at 36.5-37.5 °C by use of a heating pad and thermometer system (CMA150, Microdialysis AB, Stockholm, Sweden). The endtidal concentration of isoflurane was measured with a calibrated infrared absorption instrument (Ultima, Datex Co., Helsinki, Finland). The MAC of isoflurane was determined according to the up-and-down method by use of the tail clamp technique [4] . After surgery, the lungs were ventilated initially for 20 min with 1.5 % isoflurane. A 20-cm rubber-shod forceps was then applied with full ratcheted lock to the midportion of the rat's tail continuously for 60 s, and then removed. Any purposeful movement of the animal constituted a positive response. Non-purposeful movements, such as stiffening or grimacing, were disregarded. The isoflurane concentration was then adjusted by 10 % and administered for 20 min at the new concentration before application of a forceps was repeated. Subsequent application of the tail clamp was made proximal to previous sites of application. MAC was defined as the mean of the lowest concentration at which a negative response was observed plus the highest concentration at which a positive response was observed. After measurement of control values, the test dose of NMDA antagonist was infused intrathecally.
Statistical comparisons were made by ANOVA. Paired t tests, corrected for multiple comparisons, were performed on the MAC values. Statistical significance was accepted at a level of P : 0.05.
Physiological variables were well controlled, except for a decrease in mean arterial pressure (MAP) with APV 10 and 30 µg (9 80 mm Hg), and an increase with NMDA 10 and 30 µg. Body temperature remained unchanged during the experiment. Figure 1 shows the changes in MAC of isoflurane with administration of NMDA receptor antagonists. There were no significant differences between the 10 groups in control MAC values. APV reduced significantly the MAC of isoflurane at doses of 0.1, 1.0, 10 and 30 µg with values ranging from 17.1 to 32 % (P : 0.001 and P : 0.0001) of control. Administration of NMDA reversed the decrease in MAC of isoflurane. The reversal toward control MAC values was incomplete with APV 10 g (P : 0.05) and 30 µg (P : 0.01). MK801 decreased the MAC at 10 µg (P : 0.001) and 30 µg (P : 0.0001), but not at lower doses. Although administration of NMDA reversed the decrease in MAC of isoflurane caused by MK801 10 µg and 30 µg, it did not completely reverse the decrease caused by the higher dose of MK80l.
Comment
Administration of NMDA receptor antagonists depressed the MAC of isoflurane, but this decrease was reversed by administration of NMDA. It has been suggested that the NMDA receptor is related to the MAC of inhalation anaesthetics [5] .
NMDA antagonists are divided into two groups, a competitive, selective type and a non-competitive, non-selective type. The competitive NMDA receptor antagonist, APV, directly blocks the glutamate recognition site. MK801, a non-competitive antagonist, binds its recognition site within the NMDA receptor-activated membrane channel and thus impedes cation flow through the channel. It has been shown that intrathecal administration of APV causes significant antinociception in the mouse formalin model of tonic chemogenic nociception [6] . APV has also been shown to be antinociceptive as evidenced by its ability to attenuate non-reflex responses to noxious electrical and pressure stimuli in the rat, and also by its inhibition of the hyperalgesic effect of intrathecal administration of NMDA in mouse thermal tests [4] . Ketamine, a noncompetitive NMDA receptor antagonist, probably produces analgesic effects by disrupting sensory input in the spinal cord and thalamus. MK801 also has an antinociceptive effect, and an MK801 binding site has been reported in the spinal cord. APV decreased MAC at 0.1, 1.0, 10 and 30 µg, and this decrease was reversed by administration of NMDA. Although the reversal of NMDA effects to control values was incomplete at APV 10 and 30 µg and MK801 30 µg, this is considered to result from motor nerve dysfunction. Cahusac and colleagues [6] showed that intrathecal administration of APV 12-48 µg produced some locomotor depression in rats. Motor nerve dysfunction produced by APV could reflect an increase in extensor tone produced by a reduction in postsynaptic inhibition of motorneurones, following antagonism of synaptic excitation of Renshaw cells or other interneurones.
Recent evidence suggests that C-fibre excitatory amino acids may facilitate plastic changes in spinal cord dorsal horn neurones that are induced by noxious stimulation. There is evidence that central sensitization and wind-up are dependent on NMDA receptor activation and that NMDA receptor antagonists may prevent behaviours indicative of pain. The only NMDA receptor antagonist licensed for use in patients is the dissociative anaesthetic ketamine, which is unpleasant for most patients when given systemically. Nevertheless, extradural ketamine produces potent postoperative analgesia. It does suggest new possibilities of treatment if NMDA receptor antagonists without unacceptable side effects are developed and if they can be administered via the extradural route with no systemic actions. NMDA receptor antagonists may reduce the requirement for inhalation anaesthetics and decrease postoperative pain.
